These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 22165979)
1. Certolizumab pegol for the treatment of rheumatoid arthritis. Horton S; Walsh C; Emery P Expert Opin Biol Ther; 2012 Feb; 12(2):235-49. PubMed ID: 22165979 [TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol in rheumatoid arthritis: current update. Fechtenbaum M; Md Yusof MY; Emery P Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999 [TBL] [Abstract][Full Text] [Related]
3. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. Pasut G BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice. Punzi L; Lapadula G; Mathieu A BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236 [TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Mease PJ Rheumatology (Oxford); 2011 Feb; 50(2):261-70. PubMed ID: 20871129 [TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394 [TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of certolizumab pegol. Ferrante M; Vermeire S; Rutgeerts PJ Expert Opin Drug Saf; 2014 Feb; 13(2):255-66. PubMed ID: 24156537 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225 [TBL] [Abstract][Full Text] [Related]
13. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753 [TBL] [Abstract][Full Text] [Related]
16. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients. Aletaha D BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233 [No Abstract] [Full Text] [Related]
17. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660 [TBL] [Abstract][Full Text] [Related]
19. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675 [TBL] [Abstract][Full Text] [Related]
20. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Hazes JM; Taylor P; Strand V; Purcaru O; Coteur G; Mease P Rheumatology (Oxford); 2010 Oct; 49(10):1900-10. PubMed ID: 20547658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]